Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
- Conditions
- Refractory Monomorphic Post-Transplant Lymphoproliferative DisorderMonomorphic Post-Transplant Lymphoproliferative DisorderRecurrent Polymorphic Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative DisorderRefractory Polymorphic Post-Transplant Lymphoproliferative Disorder
- Interventions
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 18
- Registration Number
- NCT02900976
- Locations
- πΊπΈ
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
πΊπΈRiley Hospital for Children, Indianapolis, Indiana, United States
πΊπΈUniversity of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology
- Conditions
- Interventions
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 530
- Registration Number
- NCT02847130
- Locations
- π΅π·
University Pediatric Hospital, San Juan, Puerto Rico
πΊπΈSummerlin Hospital Medical Center, Las Vegas, Nevada, United States
πΊπΈMemorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 30
- Registration Number
- NCT02808650
- Locations
- πΊπΈ
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
πΊπΈChildren's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 45
- Registration Number
- NCT02724579
- Locations
- πΊπΈ
Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States
πΊπΈTufts Children's Hospital, Boston, Massachusetts, United States
πΊπΈMassachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
- Conditions
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 196
- Registration Number
- NCT02717507
- Locations
- πΊπΈ
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
πΊπΈAdvocate Children's Hospital-Oak Lawn, Oak Lawn, Illinois, United States
πΊπΈSaint Mary's Hospital, West Palm Beach, Florida, United States
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 38
- Registration Number
- NCT02642965
- Locations
- πΊπΈ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈMaine Children's Cancer Program, Scarborough, Maine, United States
π¨π¦Kingston Health Sciences Centre, Kingston, Ontario, Canada
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 280
- Registration Number
- NCT02521493
- Locations
- π¨π¦
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada
π³πΏStarship Children's Hospital, Grafton, Auckland, New Zealand
π³πΏChristchurch Hospital, Christchurch, New Zealand
Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma
- First Posted Date
- 2015-06-12
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 56
- Registration Number
- NCT02470091
- Locations
- πΊπΈ
Children's Oncology Group, Philadelphia, Pennsylvania, United States
πΊπΈSaint Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
πΊπΈChildren's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 62
- Registration Number
- NCT02452554
- Locations
- πΊπΈ
Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
πΊπΈChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 54
- Registration Number
- NCT02444884